<?xml version="1.0" encoding="UTF-8" ?>
<modsCollection xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" xmlns:slims="http://senayan.diknas.go.id" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd">
<mods version="3.3" ID="2342">
<titleInfo>
<title>Asian Journal of Pharmaceutical Sciences Volume 20, Issue 2 2025</title>
</titleInfo>
<typeOfResource manuscript="yes" collection="yes">mixed material</typeOfResource>
<genre authority="marcgt">bibliography</genre>
<originInfo>
<place><placeTerm type="text">China</placeTerm></place>
<publisher>China Medical University</publisher>
<dateIssued>2025</dateIssued>
<issuance>monographic</issuance>
<edition>Volume 20, Issue 2 2025</edition>
</originInfo>
<language>
<languageTerm type="code">id</languageTerm>
<languageTerm type="text">Indonesia</languageTerm>
</language>
<physicalDescription>
<form authority="gmd">Jurnal</form>
<extent></extent>
</physicalDescription>
<note>a b s t r a c t
Although with aggressive standards of care like surgical resection, chemotherapy, and
radiation, high-grade gliomas (HGGs) and brain metastases (BM) treatment has remained
challenging for more than two decades. However, technological advances in this field
and immunotherapeutic strategies have revolutionized the treatment of HGGs and BM.

Immunotherapies like immune checkpoint inhibitors, CAR-T targeting, oncolytic virus-
based therapy, bispecific antibody treatment, and vaccination approaches, etc., are

emerging as promising avenues offering new hope in refining patient&rsquo;s survival benefits.
However, selective trafficking across the blood-brain barrier (BBB), immunosuppressive
tumor microenvironment (TME), metabolic alteration, and tumor heterogeneity limit the
therapeutic efficacy of immunotherapy for HGGs and BM. Furthermore, to address this
concern, the NanoBioTechnology-based bioinspired delivery system has been gaining
tremendous attention in recent years. With technological advances such as Trojan horse
targeting and infusing/camouflaging nanoparticles surface with biological molecules/cells
like immunocytes, erythrocytes, platelets, glioma cell lysate and/or integrating these
strategies to get hybrid membrane for homotypic recognition. These biomimetic
nanotherapy offers advantages over conventional nanoparticles, focusing on greater target
specificity, increased circulation stability, higher active loading capacity, BBB permeability
(inherent inflammatory chemotaxis of neutrophils), decreased immunogenicity, efficient
metabolism-based combinatorial effects, and prevention of tumor recurrence by induction
of immunological memory, etc. provide new age of improved immunotherapies outcomes
against HGGs and BM. In this review, we emphasize on neuro-immunotherapy and the
versatility of these biomimetic nano-delivery strategies for precise targeting of hard-to-treat</note>
<subject authority=""><topic>Immunotherapy</topic></subject>
<subject authority=""><topic>Brain metastases</topic></subject>
<subject authority=""><topic>High-grade glioma</topic></subject>
<classification></classification><identifier type="isbn"></identifier><location>
<physicalLocation>PERPUSTAKAAN SEKOLAH TINGGI ILMU KESEHATAN SAMARINDA REPOSITORY</physicalLocation>
<shelfLocator></shelfLocator>
<holdingSimple>
<copyInformation>
<numerationAndChronology type="1">JIN0125</numerationAndChronology>
<sublocation>Perpus.Akfarsam (Jurnal Farmasi Internasional)</sublocation>
<shelfLocator>615 ASI</shelfLocator>
</copyInformation>
</holdingSimple>
</location>
<slims:digitals>
<slims:digital_item id="2214" url="https://drive.google.com/file/d/1doKeoevHiizYibDwZakBQv__1d9g1oJX/view?usp=sharing" path="/https://drive.google.com/file/d/1doKeoevHiizYibDwZakBQv__1d9g1oJX/view?usp=sharing" mimetype="text/uri-list">Volume 20, Issue 2 2025</slims:digital_item>
</slims:digitals><slims:image>Volume_20%2C_Issue_2.jpeg.jpeg</slims:image>
<recordInfo>
<recordIdentifier>2342</recordIdentifier>
<recordCreationDate encoding="w3cdtf">2026-07-10 12:24:07</recordCreationDate>
<recordChangeDate encoding="w3cdtf">2026-07-10 12:26:43</recordChangeDate>
<recordOrigin>machine generated</recordOrigin>
</recordInfo></mods></modsCollection>